{
  "success": true,
  "pagesUsed": [
    0,
    1,
    2,
    3,
    5,
    8,
    9,
    14,
    15,
    20,
    22,
    95
  ],
  "modelUsed": "gemini-3-flash-preview",
  "advanced": {
    "studyAmendments": [
      {
        "id": "amend_1",
        "number": "INT-7",
        "name": "Amendment INT-7",
        "scope": {
          "id": "f31f0ad8-0e42-4141-ab82-7c76773e201e",
          "code": "Global",
          "codeSystem": "USDM",
          "codeSystemVersion": "2024-09-27",
          "decode": "Global",
          "instanceType": "Code"
        },
        "primaryReason": {
          "id": "05117458-26ae-43ee-9feb-e6c9554fad91",
          "code": {
            "id": "8c02acd4-1211-4cfc-ba53-5c7be781c67c",
            "code": "C98782",
            "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
            "codeSystemVersion": "25.01d",
            "decode": "Protocol Amendment",
            "instanceType": "Code"
          },
          "otherReason": "Protocol Amendment",
          "instanceType": "StudyAmendmentReason"
        },
        "geographicScopes": [
          {
            "id": "dfad73d1-4bd6-439c-9aa2-c7cd47b9fe1a",
            "type": {
              "id": "c1de70e4-e17a-46a9-94b3-f87375a564c0",
              "code": "Global",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "Global",
              "instanceType": "Code"
            },
            "instanceType": "GeographicScope"
          }
        ],
        "instanceType": "StudyAmendment",
        "summary": "To update safety information to align with the ibrutinib Investigator’s Brochure (IB) to include information regarding cerebrovascular accidents as a new safety observation identified from the post-marketing setting, and to clarify that assessment of pulse/heart rate and blood pressure is expected at every protocol-specified visit until end of treatment.",
        "effectiveDate": "2019-12-19",
        "reasonIds": [
          "ar_1_1",
          "ar_1_2"
        ],
        "previousVersion": "INT-6",
        "newVersion": "INT-7"
      },
      {
        "id": "amend_2",
        "number": "INT-6",
        "name": "Amendment INT-6",
        "scope": {
          "id": "843901c6-f386-4eb0-b2b8-15b9eefcb847",
          "code": "Global",
          "codeSystem": "USDM",
          "codeSystemVersion": "2024-09-27",
          "decode": "Global",
          "instanceType": "Code"
        },
        "primaryReason": {
          "id": "82234584-d55b-4b6f-b048-fa7fa113cf55",
          "code": {
            "id": "c46676ed-b8cd-4900-b5f1-e38542e3f8ac",
            "code": "C98782",
            "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
            "codeSystemVersion": "25.01d",
            "decode": "Protocol Amendment",
            "instanceType": "Code"
          },
          "otherReason": "Protocol Amendment",
          "instanceType": "StudyAmendmentReason"
        },
        "geographicScopes": [
          {
            "id": "5cca6a65-6daa-489a-ad93-0c5fe2e87037",
            "type": {
              "id": "8ab22c30-f1b7-4aac-b608-eee3dd213b0e",
              "code": "Global",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "Global",
              "instanceType": "Code"
            },
            "instanceType": "GeographicScope"
          }
        ],
        "instanceType": "StudyAmendment",
        "summary": "The Ibrutinib Investigator’s Brochure (IB) is updated yearly with the most current AEs incidence data for ibrutinib monotherapy and combination therapy studies, and AEs leading to treatment discontinuation. Therefore, previously reported AE data have been deleted and AEs leading to treatment discontinuation are listed without incidence data.",
        "effectiveDate": "2019-08-16",
        "reasonIds": [
          "ar_2_1",
          "ar_2_2"
        ],
        "previousVersion": "INT-5",
        "newVersion": "INT-6"
      },
      {
        "id": "amend_3",
        "number": "INT-5",
        "name": "Amendment INT-5",
        "scope": {
          "id": "5df80752-3b90-4ee8-ba9d-1d32964f85d8",
          "code": "Global",
          "codeSystem": "USDM",
          "codeSystemVersion": "2024-09-27",
          "decode": "Global",
          "instanceType": "Code"
        },
        "primaryReason": {
          "id": "698dd49e-c38f-4902-ac42-f6682cc6e495",
          "code": {
            "id": "8588aaa4-9a42-4350-b328-1d2998457134",
            "code": "C98782",
            "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
            "codeSystemVersion": "25.01d",
            "decode": "Protocol Amendment",
            "instanceType": "Code"
          },
          "otherReason": "Protocol Amendment",
          "instanceType": "StudyAmendmentReason"
        },
        "geographicScopes": [
          {
            "id": "da2d1a50-6f30-4652-b794-63dc94be0cae",
            "type": {
              "id": "d8d97003-440a-497a-9fd3-e57cda83ff9e",
              "code": "Global",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "Global",
              "instanceType": "Code"
            },
            "instanceType": "GeographicScope"
          }
        ],
        "instanceType": "StudyAmendment",
        "summary": "Clarification that data collection after the clinical cutoff will include response to treatment as assessed by the investigator, and best response and progressive disease on subsequent anti-MCL therapy. The recommended supportive care for the treatment of leukostasis has been changed from leukapheresis to cytoreduction.",
        "effectiveDate": "2017-07-12",
        "reasonIds": [
          "ar_3_1",
          "ar_3_2",
          "ar_3_3"
        ],
        "previousVersion": "INT-4",
        "newVersion": "INT-5"
      },
      {
        "id": "amend_4",
        "number": "INT-4",
        "name": "Amendment INT-4",
        "scope": {
          "id": "790b3d95-7d9a-42d8-b22b-66ea4ece3a57",
          "code": "Global",
          "codeSystem": "USDM",
          "codeSystemVersion": "2024-09-27",
          "decode": "Global",
          "instanceType": "Code"
        },
        "primaryReason": {
          "id": "832f8244-11eb-404b-919f-1632a2dc6b6a",
          "code": {
            "id": "e71f4508-1f5d-4615-bb67-d073d3383cca",
            "code": "C98782",
            "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
            "codeSystemVersion": "25.01d",
            "decode": "Protocol Amendment",
            "instanceType": "Code"
          },
          "otherReason": "Protocol Amendment",
          "instanceType": "StudyAmendmentReason"
        },
        "geographicScopes": [
          {
            "id": "ca72701b-fd30-44ff-be04-6631156fc047",
            "type": {
              "id": "f68e94a1-a972-4a7c-a405-54413ec4a35e",
              "code": "Global",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "Global",
              "instanceType": "Code"
            },
            "instanceType": "GeographicScope"
          }
        ],
        "instanceType": "StudyAmendment",
        "summary": "The knowledge gained on the efficacy of ibrutinib from completed randomized clinical studies, which was not available at time of MCL3002 study design, and the lower than expected event rate are the key drivers for this amendment. The sponsor has added a second interim analysis to occur at approximately 180 PFS events.",
        "effectiveDate": "2016-04-29",
        "reasonIds": [
          "ar_4_1",
          "ar_4_2"
        ],
        "previousVersion": "INT-3",
        "newVersion": "INT-4"
      },
      {
        "id": "amend_5",
        "number": "INT-3",
        "name": "Amendment INT-3",
        "scope": {
          "id": "39f625ec-9ebf-442b-bc6d-9800ae45ab18",
          "code": "Global",
          "codeSystem": "USDM",
          "codeSystemVersion": "2024-09-27",
          "decode": "Global",
          "instanceType": "Code"
        },
        "primaryReason": {
          "id": "9e313e5c-d041-47eb-b8a5-c479e9ccd71b",
          "code": {
            "id": "b7412248-74bd-4a76-9976-731b10787a1f",
            "code": "C98782",
            "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
            "codeSystemVersion": "25.01d",
            "decode": "Protocol Amendment",
            "instanceType": "Code"
          },
          "otherReason": "Protocol Amendment",
          "instanceType": "StudyAmendmentReason"
        },
        "geographicScopes": [
          {
            "id": "b4889455-2b05-4a14-a3a2-38471beb0ce0",
            "type": {
              "id": "61a5ebf9-0df4-41d7-9aa3-cc4c9648d7a0",
              "code": "Global",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "Global",
              "instanceType": "Code"
            },
            "instanceType": "GeographicScope"
          }
        ],
        "instanceType": "StudyAmendment",
        "summary": "To update the safety language for diarrhea and other safety topics in the Introduction, the background safety information for ibrutinib has been aligned with the recently updated ibrutinib Investigator’s Brochure (IB) and other protocols within the clinical development program.",
        "effectiveDate": "2015-08-20",
        "reasonIds": [
          "ar_5_1",
          "ar_5_2"
        ],
        "previousVersion": "INT-2",
        "newVersion": "INT-3"
      },
      {
        "id": "amend_6",
        "number": "INT-2",
        "name": "Amendment INT-2",
        "scope": {
          "id": "70144f43-d949-43a5-b3da-d091c5842273",
          "code": "Global",
          "codeSystem": "USDM",
          "codeSystemVersion": "2024-09-27",
          "decode": "Global",
          "instanceType": "Code"
        },
        "primaryReason": {
          "id": "6d0396cd-b2cc-43ea-8609-9ad8905c6b11",
          "code": {
            "id": "912d4b96-d534-400a-ba17-b7fc7adbe11a",
            "code": "C98782",
            "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
            "codeSystemVersion": "25.01d",
            "decode": "Protocol Amendment",
            "instanceType": "Code"
          },
          "otherReason": "Protocol Amendment",
          "instanceType": "StudyAmendmentReason"
        },
        "geographicScopes": [
          {
            "id": "1d3c444c-a768-48cc-ba2d-76a80c79bda8",
            "type": {
              "id": "68ef2537-f294-43e2-a33a-70ad40faa3be",
              "code": "Global",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "Global",
              "instanceType": "Code"
            },
            "instanceType": "GeographicScope"
          }
        ],
        "instanceType": "StudyAmendment",
        "summary": "Discontinuation of one component of study treatment will not result in discontinuation of all study treatment. Bendamustine dose holding and discontinuation instructions have been added. Instructions for ibrutinib/placebo dose modification in the event of Grade 4 neutropenia occurring for more than 14 days are now independent of the background therapy.",
        "effectiveDate": "2014-12-15",
        "reasonIds": [
          "ar_6_1",
          "ar_6_2"
        ],
        "previousVersion": "INT-1",
        "newVersion": "INT-2"
      },
      {
        "id": "amend_7",
        "number": "INT-1",
        "name": "Amendment INT-1",
        "scope": {
          "id": "ffeefbf3-fc9a-4458-9877-0df1359b180f",
          "code": "Global",
          "codeSystem": "USDM",
          "codeSystemVersion": "2024-09-27",
          "decode": "Global",
          "instanceType": "Code"
        },
        "primaryReason": {
          "id": "6bebe0da-7c3f-46e8-b182-8fa331726690",
          "code": {
            "id": "6715f83d-abc6-4ae7-93a7-0fa4f6fae3e7",
            "code": "C98782",
            "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
            "codeSystemVersion": "25.01d",
            "decode": "Protocol Amendment",
            "instanceType": "Code"
          },
          "otherReason": "Protocol Amendment",
          "instanceType": "StudyAmendmentReason"
        },
        "geographicScopes": [
          {
            "id": "77d15615-aa2b-44a8-8c22-ebb3995f67d3",
            "type": {
              "id": "4f4a39ef-9de3-499f-aabf-4b827f4ca08b",
              "code": "Global",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "Global",
              "instanceType": "Code"
            },
            "instanceType": "GeographicScope"
          }
        ],
        "instanceType": "StudyAmendment",
        "summary": "Initial amendment to the original protocol. (Specific rationale text not provided in the extracted history summary, but listed in the version history table).",
        "effectiveDate": "2013-12-26",
        "reasonIds": [
          "ar_7_1"
        ],
        "previousVersion": "Original Protocol",
        "newVersion": "INT-1"
      }
    ],
    "amendmentReasons": [
      {
        "id": "ar_1_1",
        "code": "SAFETY",
        "description": "Safety",
        "instanceType": "AmendmentReason"
      },
      {
        "id": "ar_1_2",
        "code": "OPERATIONAL",
        "description": "Operational",
        "instanceType": "AmendmentReason"
      },
      {
        "id": "ar_2_1",
        "code": "SAFETY",
        "description": "Safety",
        "instanceType": "AmendmentReason"
      },
      {
        "id": "ar_2_2",
        "code": "ADMINISTRATIVE",
        "description": "Administrative",
        "instanceType": "AmendmentReason"
      },
      {
        "id": "ar_3_1",
        "code": "SCIENTIFIC",
        "description": "Scientific",
        "instanceType": "AmendmentReason"
      },
      {
        "id": "ar_3_2",
        "code": "SAFETY",
        "description": "Safety",
        "instanceType": "AmendmentReason"
      },
      {
        "id": "ar_3_3",
        "code": "OPERATIONAL",
        "description": "Operational",
        "instanceType": "AmendmentReason"
      },
      {
        "id": "ar_4_1",
        "code": "SCIENTIFIC",
        "description": "Scientific",
        "instanceType": "AmendmentReason"
      },
      {
        "id": "ar_4_2",
        "code": "REGULATORY",
        "description": "Regulatory",
        "instanceType": "AmendmentReason"
      },
      {
        "id": "ar_5_1",
        "code": "SAFETY",
        "description": "Safety",
        "instanceType": "AmendmentReason"
      },
      {
        "id": "ar_5_2",
        "code": "ADMINISTRATIVE",
        "description": "Administrative",
        "instanceType": "AmendmentReason"
      },
      {
        "id": "ar_6_1",
        "code": "SAFETY",
        "description": "Safety",
        "instanceType": "AmendmentReason"
      },
      {
        "id": "ar_6_2",
        "code": "OPERATIONAL",
        "description": "Operational",
        "instanceType": "AmendmentReason"
      },
      {
        "id": "ar_7_1",
        "code": "ADMINISTRATIVE",
        "description": "Administrative",
        "instanceType": "AmendmentReason"
      }
    ],
    "countries": [],
    "studySites": [],
    "summary": {
      "amendmentCount": 7,
      "countryCount": 0,
      "siteCount": 0
    },
    "geographicScope": {
      "id": "geo_1",
      "name": "Study Geographic Scope",
      "scopeType": "Global",
      "instanceType": "GeographicScope"
    }
  },
  "rawResponse": {
    "amendments": [
      {
        "number": "INT-7",
        "effectiveDate": "2019-12-19",
        "summary": "To update safety information to align with the ibrutinib Investigator’s Brochure (IB) to include information regarding cerebrovascular accidents as a new safety observation identified from the post-marketing setting, and to clarify that assessment of pulse/heart rate and blood pressure is expected at every protocol-specified visit until end of treatment.",
        "previousVersion": "INT-6",
        "newVersion": "INT-7",
        "reasons": [
          "Safety",
          "Operational"
        ]
      },
      {
        "number": "INT-6",
        "effectiveDate": "2019-08-16",
        "summary": "The Ibrutinib Investigator’s Brochure (IB) is updated yearly with the most current AEs incidence data for ibrutinib monotherapy and combination therapy studies, and AEs leading to treatment discontinuation. Therefore, previously reported AE data have been deleted and AEs leading to treatment discontinuation are listed without incidence data.",
        "previousVersion": "INT-5",
        "newVersion": "INT-6",
        "reasons": [
          "Safety",
          "Administrative"
        ]
      },
      {
        "number": "INT-5",
        "effectiveDate": "2017-07-12",
        "summary": "Clarification that data collection after the clinical cutoff will include response to treatment as assessed by the investigator, and best response and progressive disease on subsequent anti-MCL therapy. The recommended supportive care for the treatment of leukostasis has been changed from leukapheresis to cytoreduction.",
        "previousVersion": "INT-4",
        "newVersion": "INT-5",
        "reasons": [
          "Scientific",
          "Safety",
          "Operational"
        ]
      },
      {
        "number": "INT-4",
        "effectiveDate": "2016-04-29",
        "summary": "The knowledge gained on the efficacy of ibrutinib from completed randomized clinical studies, which was not available at time of MCL3002 study design, and the lower than expected event rate are the key drivers for this amendment. The sponsor has added a second interim analysis to occur at approximately 180 PFS events.",
        "previousVersion": "INT-3",
        "newVersion": "INT-4",
        "reasons": [
          "Scientific",
          "Regulatory"
        ]
      },
      {
        "number": "INT-3",
        "effectiveDate": "2015-08-20",
        "summary": "To update the safety language for diarrhea and other safety topics in the Introduction, the background safety information for ibrutinib has been aligned with the recently updated ibrutinib Investigator’s Brochure (IB) and other protocols within the clinical development program.",
        "previousVersion": "INT-2",
        "newVersion": "INT-3",
        "reasons": [
          "Safety",
          "Administrative"
        ]
      },
      {
        "number": "INT-2",
        "effectiveDate": "2014-12-15",
        "summary": "Discontinuation of one component of study treatment will not result in discontinuation of all study treatment. Bendamustine dose holding and discontinuation instructions have been added. Instructions for ibrutinib/placebo dose modification in the event of Grade 4 neutropenia occurring for more than 14 days are now independent of the background therapy.",
        "previousVersion": "INT-1",
        "newVersion": "INT-2",
        "reasons": [
          "Safety",
          "Operational"
        ]
      },
      {
        "number": "INT-1",
        "effectiveDate": "2013-12-26",
        "summary": "Initial amendment to the original protocol. (Specific rationale text not provided in the extracted history summary, but listed in the version history table).",
        "previousVersion": "Original Protocol",
        "newVersion": "INT-1",
        "reasons": [
          "Administrative"
        ]
      }
    ],
    "geographicScope": {
      "type": "Global",
      "countries": [],
      "regions": [],
      "plannedSites": null
    },
    "sites": []
  }
}